Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rhea-AI Summary

Rallybio (NASDAQ: RLYB) reported its Q4 and full year 2024 financial results, highlighting key developments and upcoming milestones. The company ended 2024 with $65.5 million in cash and equivalents, providing runway into 2H 2026.

Key financial metrics include Q4 2024 revenue of $38,000 and full-year revenue of $0.6 million, primarily from a Johnson & Johnson collaboration. Q4 net loss was $11.0 million ($0.25 per share), while full-year net loss reached $57.8 million ($1.33 per share).

Notable pipeline updates include:

• RLYB212: Phase 2 trial dosing underway with key data expected in Q2/Q3 2025
• RLYB116: Confirmatory PK/PD study initiation planned for Q2 2025
• REV102: Advancing toward Phase 1 in 2026 for hypophosphatasia treatment
• RLYB332: Showed promising preclinical results for iron overload diseases

Positive

• New collaboration agreement with Johnson & Johnson generating revenue
• Significant reduction in R&D expenses from $53.5M to $41.5M year-over-year
• Decreased G&A expenses from $25.4M to $19.6M year-over-year
• Strong cash position of $65.5M providing extended runway into 2H 2026

Negative

• Net loss of $57.8M for full year 2024
• Minimal revenue generation ($0.6M for full year)
• REV102 Phase 1 study delayed until 2026
• Workforce reduction implemented to cut costs

Insights

Financial Analyst

Rallybio's Q4 and FY 2024 financial results demonstrate meaningful progress in operational efficiency and cash management. The company reported a reduced net loss of $11.0 million for Q4 2024 (vs $20.2 million in Q4 2023) and $57.8 million for the full year (vs $74.6 million in 2023), representing EPS improvements to -$0.25 from -$0.50 quarterly and -$1.33 from -$1.84 annually.

This improved financial performance stems from two key areas: R&D expenses decreased to $41.5M from $53.5M year-over-year, while G&A costs declined to $19.6M from $25.4M. Both reductions reflect workforce adjustments and more focused development priorities. The company also generated a modest $0.6 million in revenue from its collaboration with Johnson & Johnson, providing early validation of its platform.

Most significantly, Rallybio closed 2024 with $65.5 million in cash, which management projects will fund operations into the second half of 2026. This approximately 18-24 month runway spans multiple clinical readouts without immediate financing pressure, a favorable position for a clinical-stage biotech during a period when capital remains relatively expensive.

While the cash burn rate has improved, investors should monitor the balance between fiscal discipline and adequate R&D investment, as the company advances multiple clinical programs simultaneously. The projected runway suggests a quarterly burn rate of approximately $8-10 million, which appears sustainable given the current development timeline but offers buffer for potential clinical setbacks or program expansions.

Biotechnology Specialist

Rallybio's clinical pipeline shows disciplined advancement with several potential value-creating inflection points in 2025. The RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) has reached a critical milestone with the first participant dosed in the Phase 2 trial, with data readouts expected in Q2 and Q3 2025. The impressive screening of over 14,300 pregnant women in the natural history study demonstrates robust operational execution in rare disease patient identification.

The RLYB116 complement inhibitor program revealed enhanced potential with biomarker analyses showing greater complement inhibition than initially reported, potentially expanding its application across multiple complement-mediated diseases including PNH, gMG, and APS. The planned confirmatory PK/PD study in Q2 2025 with data expected in H2 2025 represents a critical validation point for this asset.

The REV102 ENPP1 inhibitor for hypophosphatasia, developed through a joint venture with Recursion Pharmaceuticals, is advancing toward Phase 1 in 2026, with preclinical data expected in H2 2025. Meanwhile, RLYB332 showed promise in preclinical studies for diseases of iron overload, with data at ASH demonstrating superior pharmacodynamic parameters compared to competitor molecules.

The company's pipeline strategy balances near-term clinical validation (RLYB212, RLYB116) with longer-term opportunities (REV102, RLYB332). Each program targets rare diseases with significant unmet medical needs, though all remain in relatively early development stages with associated clinical risk. The multiple data readouts scheduled throughout 2025 will provide important insights into the potential value and differentiation of these assets.

— Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 —

— Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 —

— $65.5 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2024 Provides Runway into 2H 2026 —

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on recent company developments.

“We are pleased with our strong execution in 2024, and look forward to reporting on our planned milestones in 2025," said Stephen Uden, M.D., Chief Executive Officer of Rallybio. "Dosing in our RLYB212 Phase 2 trial is underway, our differentiated C5 inhibitor, RLYB116, is on track to enter a confirmatory pharmacokinetic/pharmacodynamic study in the second quarter, and our potentially best-in-class ENPP1 inhibitor for patients with hypophosphatasia, REV102, is advancing toward Phase 1 in 2026. Through exceptional execution of these programs and continued financial discipline, we are laser focused on driving value for Rallybio in 2025 and positioning the Company for sustained growth and success in the future."

Recent Business Highlights and Upcoming Milestones:

RLYB212 Program

• In February 2025, Rallybio announced that the sentinel participant was dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Pharmacokinetic (PK) and safety data from the second trimester are expected in the second quarter of 2025, with PK and safety data at the time of delivery expected in the third quarter of 2025. The Company received regulatory approval to begin the Phase 2 trial in October 2024 and initiated screening in November 2024.
  
  
• More than 14,300 pregnant women were screened in Rallybio’s FNAIT natural history study as of January 31, 2025, at which time screening was concluded at sites in the United States and Canada. Natural history data will continue to be collected in a sub-study of the Phase 2 trial, where participants at higher risk for HPA-1a alloimmunization and FNAIT who do not receive RLYB212 are eligible to enroll.
  
  
• Rallybio expects to present interim data from the FNAIT natural history study in mid-2025, including data evaluating the frequency of FNAIT risk across racial and ethnic populations.

RLYB116 Program

• In December 2024, Rallybio presented biomarker characterization analyses indicating that RLYB116 led to a meaningfully greater degree of complement inhibition in the Phase 1 multiple ascending dose (MAD) study than initially reported and as a result, may be effective in treating a broad range of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and antiphospholipid syndrome (APS).
  
  
• Rallybio plans to initiate a confirmatory clinical pharmacokinetic/pharmacodynamic (PK/PD) study in the second quarter of 2025, with data readouts from Cohorts 1 and 2 expected in the third and fourth quarter of 2025, respectively.

REV102 Program

• Rallybio advanced REV102, an ENPP1 inhibitor for the treatment of patients with hypophosphatasia (HPP), which is being developed through a joint venture with Recursion Pharmaceuticals.
  
  
• Investigational new drug application (IND)-enabling studies are underway to support the initiation of a Phase 1 study in 2026.
  
  
• Presentation of data evaluating REV102 in a preclinical model of later-onset HPP is expected in the second half of 2025.

RLYB332 Program

• In December 2024, Rallybio presented preclinical data for RLYB332 at the American Society for Hematology (ASH) annual meeting, which demonstrated that single intravenous injections of RLYB332 to humanized FcRn mice had rapid and sustained effects on PD parameters, including serum iron, unsaturated iron binding capacity (UIBC), and transferrin saturation (TSAT), with greater impact than those produced by comparator molecules.
  
  
• The favorable PD data relative to comparator molecules support RLYB332 as a long-acting, potentially best-in-class therapy for the treatment of diseases of iron overload.

Fourth Quarter and Full Year 2024 Financial Results

• Revenue: Revenue was $38 thousand for the fourth quarter of 2024 and $0.6 million for the year ended December 31, 2024, compared to no revenue in the same periods in 2023. The increase in revenue for both the fourth quarter of 2024 and the year ended December 31, 2024 was related to Rallybio's entrance into the collaboration agreement with Johnson & Johnson in the second quarter of 2024 and the recognition of revenue related to the collaboration's performance obligations.
  
  
• Research & Development (R&D) Expenses: R&D expenses were $7.4 million for the fourth quarter of 2024, compared to $15.9 million for the same period in 2023. R&D expenses were $41.5 million for the year ended December 31, 2024 compared to $53.5 million for the year ended December 31, 2023. The decrease in R&D expenses for both the fourth quarter of 2024 and the year ended December 31, 2024 was primarily due to a decrease in development costs related to RLYB212, RLYB116 and other program candidates, in addition to a decrease in payroll and personnel-related costs, largely related to the workforce reduction.
  
  
• General & Administrative (G&A) Expenses: G&A expenses were $4.3 million for the fourth quarter of 2024, compared to $5.2 million for the same period in 2023. G&A expenses were $19.6 million for the year ended December 31, 2024, compared to $25.4 million for the year ended December 31, 2023. The decrease in G&A expenses for both the fourth quarter of 2024 and the year ended December 31, 2024 was primarily due to a decrease in other general and administrative expenses including consulting fees, director and officer insurance premiums and professional fees, in addition to lower payroll and personnel-related costs, largely related to the workforce reduction and lower ongoing headcount in 2024 as compared to 2023.
  

• Net Loss and Net Loss Per Common Share: Rallybio reported a net loss of $11.0 million, or $0.25 per common share, for the fourth quarter of 2024 compared to a net loss of $20.2 million, or $0.50 per common share, for the same period in 2023. A net loss of $57.8 million, or $1.33 per common share, was reported for the year ended December 31, 2024 compared to a net loss of $74.6 million, or $1.84 per common share, for the year ended December 31, 2023.
  
  
• Cash Position: As of December 31, 2024, cash, cash equivalents, and marketable securities were $65.5 million. Rallybio expects these funds will be sufficient to support operations into the second half of 2026.

About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.

Forward-Looking Statements
This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of disclosure of preliminary PK and safety data for the sentinel participant in the RLYB212 Phase 2 trial, presenting or disclosing interim data from the FNAIT natural history study and the timing of such disclosure, whether RLYB212 will be an effective therapeutic approach for FNAIT, the timing of initiating the RLYB116 confirmatory PK/PD study and the date when data is available, including data for Cohorts 1 and 2, whether RLYB116 will be effective in treating a broad range of complement-mediated diseases, the timing of initiation of IND-enabling activities for REV102, and the timing of data in a preclinical model of later-onset HPP. The forward-looking statements in this press release are only predictions and are based largely on management’s current expectations and projections about future events and financial trends that management believes may affect Rallybio’s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the RLYB116 confirmatory PK/PD study, and the Phase 2 trial for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio’s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio’s Quarterly Report on Form 10-Q for the period ended September 30, 2024, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

Financial Tables
RALLYBIO CORPORATION
SELECTED CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
	FOR THE THREE MONTHS ENDED DECEMBER 31,								FOR THE YEAR ENDED DECEMBER 31,
(in thousands, except share and per share amounts)	2024				2023				2024				2023
Revenue:
Collaboration and license revenue	$	38			$	—			$	636			$	—
Total revenue		38				—				636				—
Operating expenses:
Research and development		7,385				15,924				41,507				53,544
General and administrative		4,261				5,188				19,625				25,388
Total operating expenses		11,646				21,112				61,132				78,932
Loss from operations		(11,608	)			(21,112	)			(60,496	)			(78,932	)
Other income:
Interest income		811				1,448				4,216				6,147
Other income		183				35				744				262
Total other income, net		994				1,483				4,960				6,409
Loss before equity in losses of joint venture		(10,614	)			(19,629	)			(55,536	)			(72,523	)
Loss on investment in joint venture		430				613				2,239				2,041
Net loss	$	(11,044	)		$	(20,242	)		$	(57,775	)		$	(74,564	)
Net loss per common share, basic and diluted	$	(0.25	)		$	(0.50	)		$	(1.33	)		$	(1.84	)
Weighted-average common shares outstanding, basic and diluted		44,660,619				40,639,567				43,544,824				40,447,388
Other comprehensive (loss) gain:
Net unrealized (loss) gain on marketable securities		(101	)			223				53				229
Other comprehensive (loss) gain		(101	)			223				53				229
Comprehensive loss	$	(11,145	)		$	(20,019	)		$	(57,722	)		$	(74,335	)

Condensed Consolidated Balance Sheets
(Unaudited)
	DECEMBER 31, 2024			DECEMBER 31, 2023
(in thousands)
Cash, cash equivalents and marketable securities	$	65,511		$	109,929
Total assets		68,108			115,620
Total liabilities		6,454			9,436
Total stockholders' equity		61,654			106,184

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312158841/en/

Investor Contacts

Samantha Tracy

Rallybio Corporation

(475) 47-RALLY (Ext. 282)

investors@rallybio.com

Kevin Lui

Precision AQ

(212) 698-8691

Kevin.Lui@precisionaq.com

Media Contact

media@rallybio.com

Source: Rallybio Corporation

FAQ

What are the expected key milestones for RLYB212 Phase 2 trial in 2025?

PK and safety data from second trimester expected in Q2 2025, with delivery-time data in Q3 2025

How much cash does Rallybio (RLYB) have and what is their runway?

$65.5M in cash, cash equivalents, and marketable securities as of December 31, 2024, providing runway into 2H 2026

What was Rallybio's (RLYB) net loss for full year 2024?

Net loss of $57.8 million, or $1.33 per common share

When will Rallybio (RLYB) begin the RLYB116 confirmatory study?

Planned initiation in Q2 2025, with data readouts expected in Q3 and Q4 2025

How many pregnant women were screened in Rallybio's FNAIT study?

Over 14,300 pregnant women were screened as of January 31, 2025